Background: Brachytherapy with iodine 125 -labeled seeds ( 125 I-seeds) implantation is increasingly being used to treat tumors because of its positional precision, minimal invasion, least damage to noncancerous tissue due to slow and continuous release of radioactivity and facilitation with modern medical imaging technologies. This study evaluates the survival and pain relief outcomes of the 125 I-seeds implantation brachytherapy in advanced pancreatic cancer patients.
I-seeds brachytherapy was associated with relief of pain in 79.7 ± 9.9% (mean ± SD) of the patients.
Conclusions: Survival of pancreatic cancer patients after 125 I-seeds implantation brachytherapy is found to be 9 months, whereas a combined treatment with 125 I-seeds brachytherapy and other therapies was associated with approximately 12 months' survival. The majority of patients who underwent 125 I-seeds brachytherapy had their pain relieved.
Introduction
Pancreatic cancer is the fourth most common cause of cancerrelated mortality. [1] In United States of America alone, 12 new cases of pancreatic cancer are diagnosed in every 100,000 individual and 11 in 100,000 persons die from this cancer, each year. Lifetime risk of developing pancreatic cancer is 1.5%. [2] It is a rapidly developing cancer which causes abdominal pain, weight loss, and jaundice. [3] Because the early signs of pancreatic cancer are not much clear, the diagnosis often remains delayed. Even the later symptoms are usually not much specific which leads to diagnosis at middle or terminal stage. By this time, cancer becomes unresectable [4] that may have invaded to surrounding areas and/or metastasized to distant organs. [5] Whereas, only 15% to 20% of pancreatic cancer patients are diagnosed at an early stage, 5-year survival after tumor resection is 20% to 25%. [6] In patients with exocrine pancreas adenocarcinoma, the 5-year survival rate for is about 3% to 6% [7] [8] [9] and for local tumor, the 5-year survival rate is about 15%. [9] Management of the unresectable pancreatic cancer is carried out with chemotherapy, radiofrequency ablation, conformal radiotherapy, interstitial brachytherapy, and brachytherapy with radioactive seeds implantation. [10] [11] [12] Local tumor control and its metastasis to other parts are the major prognostic factors. [13] Brachytherapy with iodine 125 -labeled seeds ( 125 I-seeds) implantation has become widespread in oncological use due to the development of modern facilitative medical imaging technologies. [14, 15] Computed tomography (CT)-guided percutaneous implantation of 125 I-seeds provides positional precision with minimal invasion and maintains slow and continuous release of radioactivity for the repair of nonlethal tissue damage and reoxygenation of hypoxic tissues. [12, 16] A number of studies have reported the outcomes of percutaneous 125 I-seeds implantation in pancreatic cancer patients but survival rates vary across the studies. We have carried out a systematic review of relevant studies and have performed a meta-analysis of the survival rates of the advanced stage pancreatic cancer patients after brachytherapy with 125 Iseeds implantation alone or in combination with other therapies in order to have a pooled overall as well as subgroup effect sizes of the survival in late-stage patients.
Methods
This study was performed by following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. [17] Ethics committee and/or institutional board approval was not required for this study. 
Literature search

Eligibility criteria
Relevant prospective and retrospective studies investigating brachytherapy with 125 I-seeds implantation in pancreatic cancer patients with unresectable tumor (stage II, III, IV) were illegible for inclusion. Outcomes of interest (endpoints of the present study) were: overall, 1-year, and 2-year survival rates; and percentage of patients having pain relieved.
Inclusion criterion was: Study reported the outcomes of computed tomographic (CT)-guided or endoscopic ultrasonographic (EUS)-guided 125 I-seeds implantation brachytherapy with or without other therapies after treating stage II, III, or IV stage pancreatic cancer patients. Exclusion criteria were: Study had follow-up of less than 3 months, study did not treat all patients with 125 I-seeds implantation brachytherapy, in vitro studies involving clonogenic survival rates, study did not report survival rate.
Quality assessment
Quality assessment of the included studies was performed by using Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
[18]
Data and analyses
Data regarding demographic and clinical characteristics of the patients, study design and outcome measures, and outcome data were taken from the respective research articles. Data were extracted independently by 2 authors. Interrater reliability was good (Cohen kappa = 0.94).
Random effects meta-analyses were performed to achieve inverse variance weighted overall and subgroup effect sizes of the survival rates reported in the individual studies. Subgroup analyses were performed with respect to 125 I-seeds implantation alone, 125 I-seeds implantation along with chemotherapy, 125 Iseeds implantation along with cryoablation, and 125 I-seeds implantation along with a multimodality treatment.
One-and 2-year survival rated reported by the individual studies were pooled and the significance of difference between 125 I-seeds implantation brachytherapy alone and 125 I-seeds implantation brachytherapy with other therapies was assessed with t test.
Between studies statistical heterogeneity was assessed with I 2 index. Sensitivity analyses were performed to investigate the source of high heterogeneity. Assessment of the publication bias was performed with the funnel plot asymmetry test followed by trim and fill method of missing studies estimation. All statistical procedures were performed by using Stata software (version 12 SE; Stata Corporation, Lakeway, TX, USA).
Results
Data acquisition
The literature search led to the selection of 23 studies [15, which fulfilled the eligibility criteria (Fig. 1) . Majority of the studies were retrospective in design and of moderate quality (Table 1) . A significant publication bias was also evident when tested with funnel plot asymmetry test and trim and fill method Figure 1 . A flowchart of study screening and selection process.
Han et al. Medicine (2017) 96:5 Medicine (Fig. 2) . In these studies, overall 824 patients were treated with 125 I-seeds implantation brachytherapy. Twelve studies treated patients with 125 I-seed implantation alone, whereas, 5 studies treated patients with 125 I-seeds implantation in combination with chemotherapy, 4 studies treated 125 I-seeds implantation in combination with cryosurgery (1 with radiofrequency ablation) and 2 studies utilized multimodality treatment.
Study characteristics
Average age (mean ± standard deviation; SD) of the patients was 60 ± 11 years of which 60 ± 7.4% were males. Of these, 19% were stage II, 51% stage III, and 30% stage IV pancreatic cancer patients. Anatomically, the tumor was in head of pancreas in 50% of the patients, 32% had tumor in the body of pancreas and 18% had it in the tail. On average, 30 ± 18 125 I-seeds were used per patient (7 studies data).
Study outcomes
Median follow-up was 14.2 months (7 studies data). The outcomes of the meta-analysis revealed that 125 I-seeds implantation brachytherapy alone was associated with 8.98 [95% confidence interval (CI): 6.94, 11.03] months (P < 0.00001) overall survival after the treatment (Fig. 3) with 1-year survival of 25.70 ± 9.3% (mean ± SD) and 2-year survival was 17.9 0 ± 8.6% (mean ± SD; Fig. 4 ). In stage IV pancreatic cancer patients, overall survival was 7.13 [95% CI: 4.75, 9.51] months (P < 0.00001; Fig. 5 ). Table 1 Assessment
Chen et al [19] Y (2) Was the study population clearly specified and defined? (3) Was the participation rate of eligible persons at least 50%? (4) Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study pre-specified and applied uniformly to all participants? (5) Was a sample size justification, power description, or variance and effect estimates provided? (6) For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? (7) Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? (8) For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? (9) Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? (10) Was the exposure(s) assessed more than once over time? (11) Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? (12) Were the outcome assessors blinded to the exposure status of participants? (13) Was loss to follow-up after baseline 20% or less? (14) Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? In the patients treated with 125 I-seeds implantation along with 1 or more therapies, overall survival was 11.75 [95% CI: 9.84, 13 .65] months (P < 0.00001; Fig. 3 ) with 1-year survival of 47.4 ± 22.75 (mean ± SD) % and 2-year survival was 16.97 ± 3.1% (mean ± SD; Fig. 4 ). Difference in 1-year survival rate between 125 I-seed implantation alone and 125 I-seed implantation in combination with other therapies was statistically significant (P = 0.017).
In subgroup analyses, the overall survival was 13.63 [95% CI: 9.98, 17.28] months (P < 0.00001) in patients treated with I-seeds implantation along with a multimodality treatment (Fig. 6) . Statistical heterogeneity was variable with I 2 ranged from 0% in 125 I-seeds brachytherapy-chemotherapy combination meta-analysis to 93% in 125 I-seeds brachytherapy alone metaanalysis.
Of the patients who were presented with pain before treatment, 79.7 ± 9.9% (mean ± SD) reported relief from pain after therapy (15 studies data). There was no difference in the percentage of patients receiving either 125 I-seeds brachytherapy alone or in combination with other therapies in this regard (Fig. 4) . As mean ± SD, the response rate was 64.1 ± 24.8% (8 studies data) with complete remission was observed in 10.9 ± 13.1% (6 studies data) and partial remission was observed in 26.6 ± 12.7% (6 studies data).
Discussion
The present study finds that the overall survival of pancreatic cancer patients after 125 I-seeds brachytherapy is about 9 months. A combined treatment with 125 I-seeds brachytherapy and other therapies is found to be associated with approximately 12 months of survival. However, in stage IV patients, the overall survival is about 7 months. The 125 I-seeds brachytherapy is also found to provide adequate pain relief in patients in which presentation symptom was severe pain.
Five-year survival in locally advanced pancreatic cancer patients is about 4% and the overall survival rate is 9 to 15 months which may be 3 to 6 months less in cases with metastases. [41] Pancreaticoduodenectomy is the first-line treatment option but depends on the resectability of the tumor. Therefore, the surgery is indicated for just a small proportion of the patients. Moreover, longer operative time, bleeding, and postoperative complications also need extraordinary management. Thus, in general, in the end-stage (III and IV) and in older patients, surgery remains unsuitable. [42] Among the chemotherapeutic regimens, gemcitabine modestly increases the overall survival and offers better clinical benefits in comparison with 5-fluorouracil. [43] Gemcitabine improves the overall survival up to 5 to 7 months and 20% increase in 1-year survival rate in metastatic patients. [43] Intensity-modulated radiotherapy and image-guided radiotherapy techniques also provide an effective dose while minimizing dispersion to the surrounding tissues. Both these radiotherapy regimens are associated with overall and progression-free survival of 12 and 7.6 months, respectively, to pancreatic cancer patients after preradiation chemotherapy. [44] Radioactive 125 I-seeds implantation provides the interstitial irradiation and can be a suitable option for patients who cannot be benefited by surgery. The half-life of 125 I is 59.7 days which is suitable for rapidly growing pancreatic tumor. In a 4.5 mm long seed with a diameter of 0.8 mm, 125 I is filled as Na
125
I within a sealed titanium alloy tube. Mean photonic energy in a seed is 27 to 35 KeV gamma rays which releases an initial 7 cGy/h dose followed by mean radiation of 0.694 ± 0.021 mCi (25.6 MBq) penetrable to 1.7 cm in the human tissue. [16] A continuous low-dose irradiation with 125 I-seeds has been found to cause Panc-1 cell-cycle arrest in the G2/M phase and induce apoptosis. [45] However, antiepidermal growth factor receptor (EGFR) monoclonal antibody C225 sensitized irradiation with 125 I-seeds led to apoptosis but not cell-cycle arrest in colorectal cancer cells. [46] Best time for chemotherapy is suggested to be is within 3 ± 4 days after implantation of 125 Iseeds as irradiation promotes permeability of the surrounding vasculature during this time. [47] Taken together, brachytherapy with 125 I-seeds implantation provides a comparable option for advanced pancreatic cancer patients whose benefits can be improved with combinational therapies, if feasible. It is a potential treatment for locally advanced pancreatic cancer in terms of feasibility, safety, and pain relief. However, larger and better coordinated studies are required to confirm the long-term effects of this brachytherapeutic regimen.
Conclusions
Brachytherapy with 125 I-seeds implantation leads to the overall survival of advanced pancreatic cancer patients of about 9 months and a combined treatment with 125 I-seeds brachytherapy and other therapies is found to be associated with 12 months' survival. Brachytherapy with 125 I-seeds implantation in combination with cyroablation is found to be associated with maximum survival (approximately 14 months). However, in stage IV patients, overall survival is about 7 months. The 125 Iseeds brachytherapy is also found to provide adequate pain relief in patients in which presentation symptom was severe pain. 
